Activates VPAC1 and VPAC2 receptors. Smooth muscle relaxation, vasodilation, secretion stimulation, immune modulation.
Reference facts
- Also known as
- VIP-28
- Category
- Gastrointestinal
- Mechanism of action
- Activates VPAC1 and VPAC2 receptors. Smooth muscle relaxation, vasodilation, secretion stimulation, immune modulation.
- Targets
- VPAC1, VPAC2
- Indications under research or approved
- Research — sarcoidosis (analog Aviptadil, RLF-100, COVID respiratory failure)
- Regulatory status (reference entry)
- Not FDA-approved (analog in research)
- Half-life
- ~2 minutes (rapidly degraded)
- Sequence
- HSDAVFTDNYTRLRKQMAVKKYLNSILN
- Sequence notes
- 28-residue peptide of the secretin/glucagon family.
- Molecular weight (Da)
- 3326
- First reported
- 1970
Primary References
Explore research articles about Vasoactive Intestinal Peptide (VIP)
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.